Call it a week of second chances. Multiple biotechs breathed new life into drugs sorely in need of it. Sage Therapeutics proved a drug that had failed a trial a rare form of epilepsy could be the first ever approved therapy... Read more »
Sean Parker, Facebook’s first president, just joined a group that’s a favorite topic of history listicles: He’s an innovator who has become abashed by the breakthrough he helped to create.
Parker, in an interview with Axios on Wednesday, said Facebook’s founders... Read more »
Aquam, a San Diego company with technology for cleaning out and re-lining aging utility pipelines, has raised $26 million in a growth capital round led by NewWorld Capital Group, a New York private equity firm that makes investments in sustainable... Read more »
[Updated 11/10/17, 10:25 a.m. See below.] Microsoft is applying the same model it used to launch its quantum computing and chatbot efforts to innovation in healthcare, signaling the company’s ambition and optimism about the transformative potential of artificial intelligence... Read more »
Exonics Therapeutics, one of the players in an emerging race to use gene therapy or gene editing techniques to treat Duchenne muscular dystrophy, has just landed a big round of funding to take its first treatment into clinical testing.
The Cambridge,... Read more »
Raizlabs, one of the Boston area’s best-known mobile app development shops, has been acquired by Rightpoint, a Chicago-based consulting firm.
The purchase price wasn’t disclosed. With the addition of Raizlabs, the combined companies employ 400 people across nine U.S. offices. The... Read more »
The FDA has cleared Cellectis to resume testing an experimental “off the shelf” type of cell therapy, so long as it follows a new set of measures meant to quell the safety concerns that caused the company to halt a pair... Read more »
Most of us can’t imagine going back to a time without smartphones. Having an Internet-enabled phone on one’s person makes life easier, and many of us would feel a bit naked without one. Paying for them, however, is another matter. The... Read more »
Amy Schulman is relatively new not just to Boston, but also to biotech. Before she moved to Boston in 2014 to join Polaris Partners, she was a partner at a major law firm and then worked at Pfizer in New York,... Read more »